Yorvipath
What Yorvipath is used for
Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Yorvipath
- Active substance
- palopegteriparatide
- Disease area
- Hypoparathyroidism
- Medicine group
- Calcium homeostasis
- ATC code
- H05AA
- Marketing authorisation holder
- Ascendis Pharma Bone Diseases A/S
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Yorvipath
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yorvipath used for?
Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
What is the active substance in Yorvipath?
Yorvipath contains palopegteriparatide.
Who makes Yorvipath?
The EU marketing authorisation holder is Ascendis Pharma Bone Diseases A/S.
Is Yorvipath an orphan medicine?
Yes. Yorvipath is designated an orphan medicine in the EU, for a rare disease (Hypoparathyroidism).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU